| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. Kojima S, Suzuki H, Akakura K, Shimbo M, Ichikawa T, Ito H, Department of Urology, Graduate School of Medicine, Chiba University, Japan.
|
Trump, Donald L.
|
|
2004
|
22 |
5 |
p. 433-434
2 p.
|
artikel
|
| 2 |
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer
|
Kaufman, Donald S.
|
|
2004
|
22 |
5 |
p. 393-397
5 p.
|
artikel
|
| 3 |
Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT. Iczkowski KA, Huang W, Mazzucchelli R, Pantazis CG, Stevens GR, Montironi R, Department of Pathology and Laboratory Medicine, University of Florida, Gainesville, FL.
|
Trump, Donald L.
|
|
2004
|
22 |
5 |
p. 435-
1 p.
|
artikel
|
| 4 |
Androgen receptor signaling: Mechanism of interleukin-6 inhibition. Jia L, Choong CS, Ricciardelli C, Kim J, Tilley WD, Coetzee GA, Department of Urology and Preventive Medicine, Norris Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA.
|
Bosland, Maarten C.
|
|
2004
|
22 |
5 |
p. 439-440
2 p.
|
artikel
|
| 5 |
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ, UCSF Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.
|
Trump, Donald L.
|
|
2004
|
22 |
5 |
p. 433-
1 p.
|
artikel
|
| 6 |
Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: A phase II study
|
Padrik, Peeter
|
|
2004
|
22 |
5 |
p. 387-392
6 p.
|
artikel
|
| 7 |
Contents
|
|
|
2004
|
22 |
5 |
p. vii-viii
nvt p.
|
artikel
|
| 8 |
Cystic renal cell carcinoma: Biology and clinical behavior
|
Han, Ken-ryu
|
|
2004
|
22 |
5 |
p. 410-414
5 p.
|
artikel
|
| 9 |
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D, Department of Surgery, Uniformed Services University of the Health Sciences, National Naval Medical Center, Bethesda, MD.
|
Trump, Donald L.
|
|
2004
|
22 |
5 |
p. 434-
1 p.
|
artikel
|
| 10 |
Editorial board
|
|
|
2004
|
22 |
5 |
p. iii-
1 p.
|
artikel
|
| 11 |
Erratum to ‘delivering prostate cancer prevention messages to the public: How the national cancer institute (NCI) effectively spread the word about the prostate cancer prevention trial (PCPT) results’[Uro Oncol 22 (2004) 369–376]☆
|
Smigel Croker, Kara
|
|
2004
|
22 |
5 |
p. 441-
1 p.
|
artikel
|
| 12 |
Familial primary mediastinal nonseminomatous germ-cell tumors
|
Marti, Adina
|
|
2004
|
22 |
5 |
p. 421-424
4 p.
|
artikel
|
| 13 |
HOXB13 homeodomain protein suppresses the growth of prostate cancer cells by the negative regulation of T-cell factor 4. Jung C, Kim RS, Lee SJ, Wang C, Jeng MH, Department of Urology, Walther Oncology Center, Indiana University, Indianapolis, IN.
|
Bosland, Maarten C.
|
|
2004
|
22 |
5 |
p. 440-
1 p.
|
artikel
|
| 14 |
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M, Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN), Medizinische Hochschule Hannover, Germany.
|
Trump, Donald L.
|
|
2004
|
22 |
5 |
p. 432-
1 p.
|
artikel
|
| 15 |
Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. D'Amico AV, Moul JW, Carroll PR, Cote K, Sun L, Lubeck D, Renshaw AA, Loffredo M, Chen MH, Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA.
|
Trump, Donald L.
|
|
2004
|
22 |
5 |
p. 435-436
2 p.
|
artikel
|
| 16 |
Lycopene: A novel drug therapy in hormone refractory metastatic prostate cancer
|
Ansari, M.S.
|
|
2004
|
22 |
5 |
p. 415-420
6 p.
|
artikel
|
| 17 |
Masthead/Subscription info
|
|
|
2004
|
22 |
5 |
p. iv-
1 p.
|
artikel
|
| 18 |
Mortality after cure of testicular seminoma. Zagars GK, Ballo MT, Lee AK, Strom SS, Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
|
Trump, Donald L.
|
|
2004
|
22 |
5 |
p. 431-
1 p.
|
artikel
|
| 19 |
9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901
|
Amin, Asim
|
|
2004
|
22 |
5 |
p. 398-403
6 p.
|
artikel
|
| 20 |
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR, Department of Medicine, University of New South Wales, St. George Hospital Campus, Sydney, Australia.
|
Trump, Donald L.
|
|
2004
|
22 |
5 |
p. 436-
1 p.
|
artikel
|
| 21 |
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Rubin, MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer, MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, Pienta KJ, Collins C, Sellers WR, Chinnaiyan AM, Department of Pathology, Brigham and Women's Hospital, Boston, MA.
|
Bosland, Maarten C.
|
|
2004
|
22 |
5 |
p. 436-437
2 p.
|
artikel
|
| 22 |
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
|
Trump, Donald L.
|
|
2004
|
22 |
5 |
p. 432-433
2 p.
|
artikel
|
| 23 |
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML, Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA.
|
Trump, Donald L.
|
|
2004
|
22 |
5 |
p. 431-432
2 p.
|
artikel
|
| 24 |
Renal angiomyolipoma with liposarcomatous transformation: A case report and review of the literature
|
Chandrasoma, Shahin
|
|
2004
|
22 |
5 |
p. 425-427
3 p.
|
artikel
|
| 25 |
Surgical treatment for local control of female urethral carcinoma
|
DiMarco, David S.
|
|
2004
|
22 |
5 |
p. 404-409
6 p.
|
artikel
|
| 26 |
The importance of re-evaluation in patients with cystitis glandularis associated with pelvic lipomatosis: A case report
|
Sözen, Sinan
|
|
2004
|
22 |
5 |
p. 428-430
3 p.
|
artikel
|
| 27 |
Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET. Department of Pathology, School of Medicine, University Michigan, Ann Arbor, MI.
|
Bosland, Maarten C.
|
|
2004
|
22 |
5 |
p. 437-439
3 p.
|
artikel
|
|
Tijdschrift beschrijving